|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-8.55/-1.43
|
企业价值
8.39B
|
资产负债 |
每股账面净值
-4.51
|
现金流量 |
现金流量率
--
|
损益表 |
收益
266.72M
|
每股收益
2.84
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/07 03:50 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America. |